Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?
Read More Pharma Industry News Twentyeight-Seven Therapeutics launches with $65m to develop RNA-modulating cancer therapies In an ambitious move within the biotechnology sector, a new U.S. biotech company, Twentyeight-Seven Therapeutics (28-7), has been… bypharmanewsdailySeptember 9, 2018
